Over-the-counter Drug: Bayer HealthCare AG

• Publication date: August 2012
• Report size: 50 pages

This report is a source for data, analysis and actionable intelligence on the Bayer HealthCare AG portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover data on product description, funct...

This report is a source for data, analysis and actionable intelligence on the Bayer HealthCare AG portfolio of new product development . The report provides detailed analysis on each pipeline product with data on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover data on product description, function, technology, indication, and application. The report is also supplemented with a detailed industry player profile and data on clinical trials, wherever applicable.

Scope of the Research

- Detailed industry player profile with data on business description, key industry player facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the new product development, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional data on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with data on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, industry ing and sales strategies.
- Exploit Merger and Acquisition opportunities by identifying industry players with the most innovative pipeline.
- Develop successful market-entry strategies .
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ new product development through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

In Vitro Diagnostic Industry in the United States

Data table of Contents
Data table of Contents 2
List of Tables 3
List of Figures 4
Bayer HealthCare AG - Business Overview 5
Key Facts 6
Bayer HealthCare AG - Major Products and Services 7
Bayer HealthCare AG Pipeline Products by Equipment Type 9
Bayer HealthCare AG Pipeline Products by Development Stage 10
Bayer HealthCare AG Pipeline Products by Therapy Area 11
Bayer HealthCare AG Pipeline Products by Trial Phase 12
Bayer HealthCare AG Pipeline Products by Milestone Summary 13
Ciprofloxacin Dry Powder Inhaler 14
Product Status 14
Product Description 14
FC Patch 14
Product Status 14
Product Description 14
Product Milestone 14
FC Patch Clinical Trial 15
Polyurethane Adhesive System 17
Product Status 17
Product Description 17
Silica Gel Wound Dressing 18
Product Status 18
Product Description 18
Product Milestone 18
Silica Gel Wound Dressing Clinical Trial 19
Bayer HealthCare AG - Top Competitors 21
Bayer HealthCare AG - Key Executives 22
Bayer HealthCare AG - Key Employee Biographies 23
Bayer HealthCare AG - Operations and Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 26
March 04, 2011: Bayer Extends Agreement With WHO To Fight Chagas Disease 26
January 31, 2011: BHC Announces Organizational Changes 26
December 13, 2010: Bayer Builds New Facility Worth Euros 35 Mln For Biological Development 26
July 12, 2010: Bayer HealthCare Provides US$ 2.5 Mln Funding To Advance World Hemophilia Research And Patient Care 26
April 22, 2010: Bayer HealthCare Appoints New CEO 27
April 22, 2010: Bayer HealthCare Appoints Dr. Jorg Reinhardt As New CEO 27
April 21, 2010: Bayer HealthCare Names Jorg Reinhardt As CEO 27
February 04, 2010: Bayer, Biocon Form Strategic Partnership 28
January 15, 2010: Bayer Donates Medicines Worth Euros 90,000 To Victims Of Earthquake In Haiti 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29


List of Tables

Bayer HealthCare AG, Major development 1
Bayer HealthCare AG Key Pipeline Products by Equipment Type 1
Bayer HealthCare AG Key Pipeline Products by Therapy Area 1
Bayer HealthCare AG Key Pipeline Products by Development Stage 1
Bayer HealthCare AG Key Pipeline Products by Trial Phase 1
Bayer HealthCare AG, Major development 6
Bayer HealthCare AG, Major Products and Services 7
Bayer HealthCare AG Number of Pipeline Products by Equipment Type 9
Bayer HealthCare AG Pipeline Products by Equipment Type 9
Bayer HealthCare AG Number of Pipeline Products by Development Stage 10
Bayer HealthCare AG Pipeline Products by Development Stage 10
Bayer HealthCare AG Number of Pipeline Products by Therapy Area 11
Bayer HealthCare AG Pipeline Products by Therapy Area 11
Bayer HealthCare AG Number of Pipeline Products by Trial Phase 12
Bayer HealthCare AG Pipeline Products by Trial Phase 12
Bayer HealthCare AG Number of Pipeline Products By Milestone Summary 13
Bayer HealthCare AG Pipeline Products by Milestone Summary 13
Ciprofloxacin Dry Powder Inhaler - Product Status 14
Ciprofloxacin Dry Powder Inhaler - Product Description 14
FC Patch - Product Status 14
FC Patch - Product Description 14
FC Patch - Product Milestone 14
FC Patch - Multi-Center, Open, Randomized, Parallel Group Comparison of Cycle Control for Seven Cycles and Endometrial Safety in a Subgroup for Thirteen Cycles of Contraceptive Patch SH P00331F ( vs a Contraceptive Comparator Patch in 400 Healthy Female Volunteers) 15
FC Patch - A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch 15
FC Patch - Transdermal Contraception Patch: EU Cycle Control Study Versus EVRA 16
Polyurethane Adhesive System - Product Status 17
Polyurethane Adhesive System - Product Description 17
Silica Gel Wound Dressing - Product Status 18
Silica Gel Wound Dressing - Product Description 18
Silica Gel Wound Dressing - Product Milestone 18
Silica Gel Wound Dressing - Clinical trial to evaluate Silica gel wound dressing in patients suffering from chronic venous leg ulcers 19
Silica Gel Wound Dressing - Randomized Standard-of-Care-Controlled Trial of a Silica Gel Fiber (SGF) Wound Dressing in the Treatment of Chronic Venous Leg Ulcers 19
Bayer HealthCare AG, Key Executives 22
Bayer HealthCare AG, Key Employee Biographies 23
Bayer HealthCare AG, Other Locations 24
Bayer HealthCare AG, Subsidiaries 24


List of Figures

Bayer HealthCare AG Pipeline Products by Equipment Type 9
Bayer HealthCare AG Pipeline Products by Development Stage 10
Bayer HealthCare AG Pipeline Products by Therapy Area 11
Bayer HealthCare AG Pipeline Products by Trial Phase 12
Bayer HealthCare AG Pipeline Products by Milestone Summary 13

Companies mentioned November artis Pharma AG
Rite Aid Corporation
Mitsubishi Chemical Holdings Corporation
Merck & Co., Inc.
Becton, Dickinson and Firms
ARKRAY, Inc.
LifeScan, Inc.
F. Hoffmann-La Roche Ltd.
Terumo Corporation